Signaling pathways
-
BA7699 MilvexianSummary: Milvexian is an orally effective, small-molecule, reversible, direct-binding antagonist with values of 0.11, 0.38, 0.64, 490, and 350 nM in humans, rabbits, dogs, rats, and mice, respectively. - BA7700 BMS-262084Summary: BMS-262084 is a potent, selective and irreversible inhibitor.
- BA7701 CiraparantagSummary: Ciraparantag is an inhibitor.
- BA7702 DarexabanSummary: Darexaban (YM150) is a potent, selective and orally active factor Xa inhibitor.
- BA7703 BMS-962212Summary: BMS-962212 is a direct, reversible, selective inhibitor.
- BA7704 FrunexianSummary: Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activating factor XI, targeting FactorXIa.
- BA7705 ZifaxabanSummary: Zifaxaban is an orally active, competitive and selective factor Xa inhibitor.
- BA7706 CP-609754Summary: CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.
- BA7707 FGTI-2734Summary: FGTI-2734 is a C-terminal farnesyltransferase and geranylgeranyltransferase-1 inhibitor.
- BA7708 BMS-214662Summary: BMS-214662 is an effective and selective inhibitor.